0.92% -0.135

Viatris Inc (VTRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1111)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Prossima data di guadagno

Ultimi documenti SEC

VTRS's Discussions on Twitter

Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTRS Viatris Inc	14.57	16.94B	14.33B	-3.79B	1.84B	-3.17
TAK Takeda Pharmaceutical Co Adr	17.68	57.56B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	123.04	53.17B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.26	46.62B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	31.81	38.33B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	482.33	21.48B	3.13B	1.27B	1.12B	26.39

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-09	Aggiornamento	UBS	Neutral → Buy
2026-01-16	Aggiornamento	Argus	Hold → Buy
2025-12-09	Iniziato	Barclays	Overweight
2025-10-15	Iniziato	Truist	Buy
2025-06-06	Iniziato	Goldman	Neutral
2024-07-19	Ripresa	Jefferies	Buy
2023-10-23	Downgrade	BofA Securities	Neutral → Underperform
2023-06-23	Downgrade	Barclays	Equal Weight → Underweight
2023-04-24	Downgrade	Barclays	Overweight → Equal Weight
2023-02-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Aggiornamento	Jefferies	Hold → Buy
2022-11-10	Aggiornamento	UBS	Sell → Neutral
2022-11-08	Aggiornamento	Piper Sandler	Underweight → Neutral
2022-10-21	Ripresa	Jefferies	Hold
2022-06-14	Iniziato	UBS	Sell
2022-05-10	Downgrade	Piper Sandler	Neutral → Underweight
2022-03-01	Downgrade	BofA Securities	Buy → Neutral
2022-03-01	Downgrade	Raymond James	Outperform → Mkt Perform
2021-06-15	Iniziato	Citigroup	Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2021-03-08	Downgrade	Goldman	Buy → Neutral
2021-03-02	Downgrade	JP Morgan	Overweight → Neutral
2021-02-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2021-01-05	Iniziato	Argus	Hold
2020-12-14	Iniziato	Bernstein	Mkt Perform

Mostra tutto

Viatris Inc Borsa (VTRS) Ultime notizie

Viatris Inc Azioni (VTRS) Dati Finanziari

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Borsa (VTRS) Ultime notizie

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq

Viatris Unit Can't Ax Patent For Anemia Drug Evrenzo - Law360

Generic Pharma Q4 2025 Earnings Review: Revenue Beat, Stock DeclineNews and Statistics - IndexBox

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive - FinancialContent

VTRS Financials: Income Statement, Balance Sheet & Cash Flow | Viatris Inc Ord Shs - Stock Titan

A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review - simplywall.st

Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value - Insider Monkey

Viatris Inc. stock rises Monday, outperforms market - MarketWatch

Viatris Inc. (VTRS) Stock Report: Navigating the Healthcare Giant’s 3.22% Dividend Yield and Revenue Growth - DirectorsTalk Interviews

Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 - Finviz

Viatris Earnings Call Highlights Slow Growth, Cash Strength - TipRanks

UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve - Insider Monkey

UBS raises Viatris stock price target to $20 on cost savings - Investing.com India

Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media

UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com

Viatris Inc. (NASDAQ:VTRS) Q4 2025 Earnings Call Transcript - Insider Monkey

Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date - Finviz

JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating - marketscreener.com

A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update - Yahoo Finance

Viatris (VTRS) Quarterly Loss Of US$340.1 Million Tests Profitability Turnaround Narrative - Sahm

Decoding Viatris Inc (VTRS): A Strategic SWOT Insight - GuruFocus

Viatris Earnings: Drugmaker Left 2025 With Momentum; 2026 to Bring Stability and Broad-Based Growth - Morningstar

BofA raises Viatris stock price target on cost-cutting plan - Investing.com

Viatris Inc. stock falls Thursday, underperforms market - MarketWatch

Is Strong Q4 Revenue And Steady Dividend Policy Altering The Investment Case For Viatris (VTRS)? - simplywall.st

Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives - Morningstar

Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Finviz

Earnings call transcript: Viatris Q4 2025 earnings beat forecasts, stock up - Investing.com

Viatris Q4 2025 slides: earnings beat, major cost-cutting plan - Investing.com

Viatris Q4 2025 slides: earnings beat, major cost-cutting plan By Investing.com - Investing.com South Africa

Restructuring: Viatris to cut global workforce by about 10% - Pittsburgh Post-Gazette

Viatris Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025 - The Globe and Mail

The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy - FinancialContent

Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance

Viatris Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Viatris Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:VTRS) 2026-02-26 - Seeking Alpha

Viatris forecasts 2026 profit below estimates on India manufacturing woes - marketscreener.com

Viatris Launches Major Restructuring After Strong 2025 Results - TipRanks

Viatris maintains annual dividend at 48 cents for 2026 - Investing.com

Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2026 - marketscreener.com

Viatris Inc. Provides Earnings Guidance for the Fiscal Year 2026 - marketscreener.com

Viatris shares fall on lower-than-expected 2026 profit outlook - Investing.com Australia

Viatris Posts Narrower Loss In Q4; Expects Workforce Reduction Of Up To Approx. 10% - Nasdaq

Viatris Q4 25 Earnings Conference Call At 8:30 AM ET - Nasdaq

Viatris beats on Q4; eyes 10% staff reduction (VTRS:NASDAQ) - Seeking Alpha

Viatris : VTRS Q4 2025 Earnings Presentation FINAL - marketscreener.com

Viatris : VTRS Q4 2025 Earnings Infographic - marketscreener.com

Viatris beats estimates, stock edges up - Investing.com

Viatris Inc Azioni (VTRS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a VTRS